Insmed Incorporated (NASDAQ:INSM) Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 33.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,615 shares of the biopharmaceutical company's stock after selling 13,204 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC's holdings in Insmed were worth $1,838,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Jennison Associates LLC boosted its position in Insmed by 0.6% during the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company's stock worth $53,424,000 after acquiring an additional 4,560 shares during the last quarter. Capital CS Group LLC acquired a new stake in Insmed in the 4th quarter worth about $586,000. abrdn plc boosted its stake in Insmed by 159.5% in the 4th quarter. abrdn plc now owns 289,653 shares of the biopharmaceutical company's stock worth $19,998,000 after buying an additional 178,041 shares during the last quarter. Moody Aldrich Partners LLC acquired a new stake in Insmed in the 4th quarter worth about $2,449,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Insmed by 14.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 37,934 shares of the biopharmaceutical company's stock worth $2,619,000 after buying an additional 4,882 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $90.00 target price on shares of Insmed in a research report on Monday. Wells Fargo & Company lifted their price target on shares of Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a report on Wednesday, February 19th. Royal Bank of Canada reiterated an "outperform" rating and issued a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a report on Friday, February 7th. Finally, UBS Group reduced their target price on Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $94.63.

Insmed Trading Down 3.0%

Shares of INSM opened at $65.71 on Wednesday. The stock's 50-day moving average is $72.17 and its two-hundred day moving average is $73.26. The stock has a market cap of $11.95 billion, a PE ratio of -11.75 and a beta of 0.84. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. During the same period last year, the firm posted ($1.06) earnings per share. The business's revenue was up 22.9% on a year-over-year basis. Equities analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In other Insmed news, CFO Sara Bonstein sold 18,322 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total value of $1,471,439.82. Following the transaction, the chief financial officer now directly owns 118,863 shares of the company's stock, valued at $9,545,887.53. This represents a 13.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO William Lewis sold 18,750 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the completion of the sale, the chief executive officer now directly owns 334,186 shares in the company, valued at $27,079,091.58. This represents a 5.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 88,232 shares of company stock valued at $6,868,473. Corporate insiders own 3.00% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.